Andreas Charidimou1, Andre Philippe Peeters, Rolf Jäger, Zoe Fox, Yves Vandermeeren, Patrice Laloux, Jean-Claude Baron, David John Werring. 1. From the Stroke Research Group, Department of Brain Repair and Rehabilitation (A.C., D.J.W.), and Lysholm Department of Neuroradiology (R.J.), UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; Department of Neurology (A.P.P.), Cliniques Universitaires UCL Saint Luc, Brussels, Belgium; Department of Brain Repair and Rehabilitation (R.J.), and Biomedical Research Centre, UCL and the Education Unit (Z.F.), UCL Institute of Neurology, Queen Square, London, UK; Department of Neurology, CHU Mont-Godinne (Y.V., P.L.), and Institute of Neuroscience (Y.V., P.L.), Université Catholique de Louvain, Brussels, Belgium; Department of Clinical Neurosciences (J.-C.B.), University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; and UMR 894 INSERM-Université Paris 5, Sorbonne Paris Cité, Paris, France.
Abstract
OBJECTIVE: To investigate whether cortical superficial siderosis (cSS) on MRI, especially if disseminated (involving more than 3 sulci), increases the risk of future symptomatic lobar intracerebral hemorrhage (ICH) in cerebral amyloid angiopathy (CAA). METHODS: European multicenter cohort study of 118 patients with CAA (104 with baseline symptomatic lobar ICH) diagnosed according to the Boston criteria. We obtained baseline clinical, MRI, and follow-up data on symptomatic lobar ICH. Using Kaplan-Meier and Cox regression analyses, we investigated cSS and ICH risk, adjusting for known confounders. RESULTS: During a median follow-up time of 24 months (interquartile range 9-44 months), 23 of 118 patients (19.5%, 95% confidence interval [CI]: 12.8%-27.8%) experienced symptomatic lobar ICH. Any cSS and disseminated cSS were predictors of time until first or recurrent ICH (log-rank test: p = 0.0045 and p = 0.0009, respectively). ICH risk at 4 years was 25% (95% CI: 7.6%-28.3%) for patients without siderosis; 28.9% (95% CI: 7.7%-76.7%) for patients with focal siderosis; and 74% (95% CI: 44.1%-95.7%) for patients with disseminated cSS (log-rank test: p = 0.0031). In Cox regression models, any cSS and disseminated cSS were both independently associated with increased lobar ICH risk, after adjusting for ≥ 2 microbleeds and age (hazard ratio: 2.53; 95% CI: 1.05-6.15; p = 0.040 and hazard ratio: 3.16; 95% CI: 1.35-7.43; p = 0.008, respectively). These results remained consistent in sensitivity analyses including only patients with symptomatic lobar ICH at baseline. CONCLUSIONS: Our findings indicate that cSS, particularly if disseminated, is associated with an increased risk of symptomatic lobar ICH in CAA. cSS may help stratify future bleeding risk in CAA, with implications for prognosis and treatment.
OBJECTIVE: To investigate whether cortical superficial siderosis (cSS) on MRI, especially if disseminated (involving more than 3 sulci), increases the risk of future symptomatic lobar intracerebral hemorrhage (ICH) in cerebral amyloid angiopathy (CAA). METHODS: European multicenter cohort study of 118 patients with CAA (104 with baseline symptomatic lobar ICH) diagnosed according to the Boston criteria. We obtained baseline clinical, MRI, and follow-up data on symptomatic lobar ICH. Using Kaplan-Meier and Cox regression analyses, we investigated cSS and ICH risk, adjusting for known confounders. RESULTS: During a median follow-up time of 24 months (interquartile range 9-44 months), 23 of 118 patients (19.5%, 95% confidence interval [CI]: 12.8%-27.8%) experienced symptomatic lobar ICH. Any cSS and disseminated cSS were predictors of time until first or recurrent ICH (log-rank test: p = 0.0045 and p = 0.0009, respectively). ICH risk at 4 years was 25% (95% CI: 7.6%-28.3%) for patients without siderosis; 28.9% (95% CI: 7.7%-76.7%) for patients with focal siderosis; and 74% (95% CI: 44.1%-95.7%) for patients with disseminated cSS (log-rank test: p = 0.0031). In Cox regression models, any cSS and disseminated cSS were both independently associated with increased lobar ICH risk, after adjusting for ≥ 2 microbleeds and age (hazard ratio: 2.53; 95% CI: 1.05-6.15; p = 0.040 and hazard ratio: 3.16; 95% CI: 1.35-7.43; p = 0.008, respectively). These results remained consistent in sensitivity analyses including only patients with symptomatic lobar ICH at baseline. CONCLUSIONS: Our findings indicate that cSS, particularly if disseminated, is associated with an increased risk of symptomatic lobar ICH in CAA. cSS may help stratify future bleeding risk in CAA, with implications for prognosis and treatment.
Authors: Andreas Charidimou; Jun Ni; Sergi Martinez-Ramirez; Anastasia Vashkevich; Alison Ayres; Jonathan Rosand; Edip M Gurol; Steven M Greenberg; Anand Viswanathan Journal: Cerebrovasc Dis Date: 2016-01-12 Impact factor: 2.762
Authors: Jun Ni; Eitan Auriel; Jenelle Jindal; Alison Ayres; Kristin M Schwab; Sergi Martinez-Ramirez; Edip M Gurol; Steven M Greenberg; Anand Viswanathan Journal: Cerebrovasc Dis Date: 2015-04-08 Impact factor: 2.762
Authors: Andreas Charidimou; Gregoire Boulouis; M Edip Gurol; Cenk Ayata; Brian J Bacskai; Matthew P Frosch; Anand Viswanathan; Steven M Greenberg Journal: Brain Date: 2017-07-01 Impact factor: 13.501
Authors: Gregoire Boulouis; Andreas Charidimou; Michael J Jessel; Li Xiong; Duangnapa Roongpiboonsopit; Panagiotis Fotiadis; Marco Pasi; Alison Ayres; M Emily Merrill; Kristin M Schwab; Jonathan Rosand; M Edip Gurol; Steven M Greenberg; Anand Viswanathan Journal: Neurology Date: 2017-01-27 Impact factor: 9.910
Authors: Gregoire Boulouis; Andreas Charidimou; Marco Pasi; Duangnapa Roongpiboonsopit; Li Xiong; Eitan Auriel; Ellis S van Etten; Sergi Martinez-Ramirez; Alison Ayres; Anastasia Vashkevich; Kristin M Schwab; Jonathan Rosand; Joshua N Goldstein; M Edip Gurol; Steven M Greenberg; Anand Viswanathan Journal: J Neurol Sci Date: 2017-07-09 Impact factor: 3.181
Authors: Thanakit Pongpitakmetha; Panagiotis Fotiadis; Marco Pasi; Gregoire Boulouis; Li Xiong; Andrew D Warren; Kristin M Schwab; Jonathan Rosand; M Edip Gurol; Steven M Greenberg; Anand Viswanathan; Andreas Charidimou Journal: Neurology Date: 2020-04-13 Impact factor: 9.910
Authors: Andreas Charidimou; Sergi Martinez-Ramirez; Yael D Reijmer; Jamary Oliveira-Filho; Arne Lauer; Duangnapa Roongpiboonsopit; Matthew Frosch; Anastasia Vashkevich; Alison Ayres; Jonathan Rosand; Mahmut Edip Gurol; Steven M Greenberg; Anand Viswanathan Journal: JAMA Neurol Date: 2016-08-01 Impact factor: 18.302